News – Page 2 – BioTuesdays

Developments

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

iBio’s (NYSE American:IBIO) plant-based FastPharming System and customized FastGlycaneering tools were featured in an article in Genetic Engineering & Biotechnology. Sylvain Marcel, Ph.D., VP of protein expression...

January 11, 2021

Developments

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Closely-held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...

January 7, 2021

Executive Moves

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

Closely-held Fibrocor Therapeutics appointed Joseph Walewicz, a biotech veteran with more than 25 years of experience in finance, capital markets and business development, as CFO. Prior to joining Fibrocor, Mr. Walewicz...

January 7, 2021

Developments

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) executed of a definitive supply agreement with Heritage Cannabis Holdings (CSE:CANN; OTCQX:HERTF) to manufacture and supply filmstrip products containing 10 mg of cannabidiol (CBD) using...

January 7, 2021

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Markets

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

January 6, 2021

Developments

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...

January 5, 2021

Markets

BTIG starts Delcath Systems at buy; PT $23

BTIG initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and price target of $23. The stock closed at $16.91 on Jan. 4. Delcath has developed HEPZATO, a percutaneous hepatic perfusion system that “we...

January 5, 2021

Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021

Markets

WB ups VistaGen Therapeutics to OP; fair value estimate $9

William Blair upgraded VistaGen Therapeutics (NASDAQ:VTGN) to “outperform” with a fair value estimate of $9, citing a “clearly skewed risk/reward” for the shares. The stock closed at $1.94 on Dec. 31. VistaGen is...

January 4, 2021

Developments

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive top line data from the low dose cohort in its Phase 2a AMBITION clinical trial of 75 mg CRV431, an oral, once-daily novel cyclophilin inhibitor, for the treatment...

December 30, 2020

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

iBio’s FastPharming featured in Genetic Engineering & Biotechnology News

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Fibrocor Therapeutics names biotech veteran Joseph Walewicz as CFO

IntelGenx receives first purchase order for CBD filmstrips from Heritage Cannabis

Profound Medical Q4 preliminary revenue beats consensus estimates

Stifel starts Neoleukin Therapeutics at buy; PT $18

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

BTIG starts Delcath Systems at buy; PT $23

HCW starts Kazia Therapeutics at buy; PT $17

WB ups VistaGen Therapeutics to OP; fair value estimate $9

Hepion Pharma posts positive Phase 2a low dose data for CRV431 in advanced NASH

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter